1 / 16

EUGIS

EUGIS. European Union Garlic Inflammation Study in Humans. Background. No clear indications that ‘garlic’ influences lipid metabolism Indications from cell and animal studies that ‘garlic’ may influence inflammation parameters

loan
Download Presentation

EUGIS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. EUGIS European Union Garlic Inflammation Study in Humans

  2. Background • No clear indications that ‘garlic’ influences lipid metabolism • Indications from cell and animal studies that ‘garlic’ may influence inflammation parameters • Cardiovascular disease (atherosclerosis) shares common features with inflammation • Current treatment strategies for atherosclerosis also focus on inflammation

  3. Aim Study the effects of garlic on inflammatory biomarkers of atherosclerotic disease and on cancer biomarkers in man • Primary endpoint: changes in C-reactive protein ( CRP) • Secondary endpoints: • Indicators of lipid metabolism • Biochemical markers of inflammation • Bloodpressure / heart rate variability • Biomarkers for anti-carcinogenic effects

  4. Inclusion criteria • Able and willing to give informed consent • 90 subjects of either gender* • Aged between 40-75 years • Smoking≥ 10 cigarettes/day and BMI≥ 24.5 kg/m2 * Power calculation to find a reduction of 30% in plasma CRP levels with = 0.05 and a power of 80% about 30 subjects per group are needed

  5. Exclusion criteria • Any major clinical significant abnormality detected by a general health questionnaire or by blood sampling • Chronic drug treatment /use of medication • Participation in prior study in the last 3 months or blood donation • Inadequate use of contraceptives / pregnancy / lactating women • History of alcohol / drug abuse • Positive test results for HepB/C or HIV • Dislike of garlic

  6. Experimental design • Double dummy placebo-controlled trial • 3 parallel groups (n=30) I.C. / screening Intervention period 4 - 5 11-12 weeks -2 0 Blood and urine collection

  7. 12-weeks treatment • 1. Garlic (from EU-sponsored Printanor 2001) • Lichtwer capsule preparation (300 mg) • 2.1g daily (3 cap - breakfast & 4 cap at dinner) • 2. Atorvastatin: • 40 mg/day daily at dinner • 3. Placebo: • garlic and statin placebo daily

  8. Measurements • Safety: • Parameters of muscle and liver function • Haematology • Clinical: • Blood pressure • 12 lead ECG (HR, conduction) • Heart Rate Variability (HRV)

  9. Measurements • Biochemical: • Cholesterol, HDL, and triglycerides; • CRP, vWF, Fbg, and cytokines after whole blood stimulation without or with LPS (TNF-α, IL-10); • Sensitivity of leukocytes to inflammatory stimulus; • Cancer biomarkers: anti-oxidant enzymes (GPX, SOD), DNA damage (Comet assay), anti-mutagenic properties of urine (Ames test); • Metabolites of garlic compounds in plasma and urine;

  10. Additional measurements suggested in the EU proposal • SAA, and PAI-1 • s-VCAM / s-ICAM / s-Selectine • MCP-1 and other chemokines • Endothelin 1 and 3 • Plasma ox-LDL • Urine isoprostanes

  11. Current study status •  Subjects at information sessions: >148 •  Subjects signing IC: 142 •  Subjects randomised : 92 •  Subjects completed: 84 •  Subjects withdrawn: 8 (6 non-related AEs) • Entire clinical study period: < 5 months! • last samples at Jan 15th

  12. Study population - baseline • Female • n = 47 • age: 40-67 yrs • BMI: 29.6 (SD: 4.1) kg/m2 • BP: 124 (18) / 76 (12) mm Hg • Male • n = 37 • age: 40-63 yrs • BMI: 29.3 (SD: 3.2) kg/m2 • BP: 130 (11) / 82 (10) mm Hg

  13. Baseline lipids • Female • Total Cholesterol: 5.60 (1.01) mmol/L (3.9-7.3) • HDL-Cholesterol: 1.35 (0.32) mmol/L (>1.16) • LDL-Cholesterol: 3.52 (0.95) mmol/L • Triglycerides: 1.63 (0.95) mmol/L(0.8-1.94) • Male • Total Cholesterol: 5.71 (1.04) mmol/L (3.9-7.3) • HDL-Cholesterol: 1.11 (0.32) mmol/L (>0.90) • LDL-Cholesterol: 3.54 (0.99) mmol/L • Triglycerides: 2.35 (1.32) mmol/L(0.8-1.94)

  14. Adverse Events • AE’s • Headache: • 52 episodes in 41 subjects • Abdominal discomfort • 36 episodes in 26 subjects • Other • 60 various events (URT infection, ‘pains’, intercurrents)

  15. PLAN • All samples have been / are being shipped • Unblinding next week • Primary parameter laboratory analysis completed at Jan 31st • Stats analysis time allocated • Main report around March 1st 2004 • Additional reports: to be discussed

  16. THANKS • Lichtwer • S Striegl • T Haffner • LUMC pharmacy • R Press • TNO-PG • P Meijer • R Kret • R Streunding • CHDR • M van Doorn • I Kamerling • Nursing staff • Participants who tolerated 2.1 gram garlic/day

More Related